Integrated quantitative proteomic workflows across cells, tissue, and plasma – anchored by the globally patented BioTAS™ platform for blood-based analysis and regulated clinical integration.
Proteas Health integrates quantitative proteomic workflows into therapeutic and diagnostic development to enable target engagement assessment, systemic drug response evaluation, and structured translational advancement toward clinical-scale assay deployment.
High-resolution quantitative proteome and phosphoproteome profiling to resolve pathway activity, target engagement, and systemic biological response.
Quantitative plasma proteomic analysis enabled by the BioTAS™ platform to characterize systemic drug effects, define stratification strategies, and establish protein signatures for assay translation.
Multiplexed quantitative protein measurement workflows designed for translational confirmation and integration into clinical development programs, including deployment within CLIA-aligned laboratory environments.
BioTAS™ is a globally patented proteomics infrastructure (PCT/US2021/063407) integrating controlled plasma isolation, high-resolution quantitative mass spectrometry, and AI-enabled modeling to deliver reproducible protein measurement across decentralized and CLIA-aligned laboratory environments.
Designed for program integration rather than exploratory analysis, our workflows enable multi-site integration, reproducible protein measurement and compatibility with regulated laboratory environments.
Proteomic integration from preclinical research through Phase I–III clinical trials, supporting target engagement assessment, systemic pharmacodynamic evaluation, and mechanistic validation.
Development and analytical validation of quantitative plasma assays supporting scalable implementation within CLIA-aligned laboratory environments.
Mechanistic proteomic collaboration for publication-grade biological investigation.
